Weinstein M R, Dedier H, Brunton J, Campbell I, Conly J M
Department of Medicine, The Toronto Hospital, University of Toronto, Ontario, Canada.
Clin Infect Dis. 1999 Aug;29(2):361-6. doi: 10.1086/520216.
In a prospective observational cohort study designed to assess the role of oral bacitracin solution plus doxycycline in the eradication of intestinal carriage of vancomycin-resistant Enterococcus faecium (VREF) in patients on a renal ward, rectal swab specimens were obtained from 15 treated and 24 control patients. Cultures of the rectal swabs were negative for 15 (100%) of the antibiotic-treated vs. eight (33.3%) of the untreated patients (P < .001) on day 14. However, follow-up for a mean of 127 and 130 days revealed 9 of 15 (60%) and 15 of 24 (62.5%) in the treated and untreated cohorts (P = .86), respectively, carried VREF intermittently or persistently. Quantitative VREF stool cultures in the treated cohort revealed an initial 3.1-log10/g decrease, but there was an increase to pretreatment levels at 2-4 and 5-7 weeks post-treatment (7.8 and 7.4 log10/g). Oral bacitracin and doxycycline were not efficacious in reducing the carriage of VREF beyond the 2-week interval during which they were given.
在一项前瞻性观察性队列研究中,旨在评估口服杆菌肽溶液加强力霉素在根除肾内科病房患者耐万古霉素屎肠球菌(VREF)肠道携带中的作用,从15例接受治疗的患者和24例对照患者中获取直肠拭子标本。在第14天,抗生素治疗组的15例患者(100%)直肠拭子培养阴性,而未治疗组的24例患者中有8例(33.3%)阴性(P<0.001)。然而,平均随访127天和130天后,治疗组和未治疗组分别有15例中的9例(60%)和24例中的15例(62.5%)间歇性或持续性携带VREF(P=0.86)。治疗组的VREF粪便定量培养显示最初下降了3.1个对数10/g,但在治疗后2 - 4周和5 - 7周增加到治疗前水平(7.8和7.4对数10/g)。口服杆菌肽和强力霉素在给药的2周间隔期后,在减少VREF携带方面无效。